Related Experiment Video
Updated: May 6, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Vancomycin-resistant gut commensal Clostridium innocuum emerges as a pathobiont through synergy with toxigenic
Chia-Jung Kuo1, Tsui-Shan Hsu2, Chin-Ming Hsu2
1School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; Chang Gung Microbiota Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Abstract:
Clostridium innocuum is increasingly detected in patients with Clostridioides difficile infection (CDI), particularly following vancomycin treatment, and is associated with delayed clinical recovery and poor outcomes. Although C. innocuum lacks classical toxins, its lipopolysaccharide-like cytotoxic activity and emerging pathogenic role remain poorly understood. In this study, we conducted co-infection models to explore the interactions between toxigenic C. difficile and C. innocuum in human intestinal epithelial cells. Our results showed that C. innocuum alone exhibited minimal cytotoxicity; however, its presence significantly enhanced cell death and barrier disruption during co-infection with toxigenic C. difficile. Pre-infection with toxigenic C. difficile promoted C. innocuum translocation across epithelial monolayers, indicating that toxin-mediated barrier damage facilitates deeper colonization. Co-infection further activated p53-mediated stress signaling and altered the BAX/BCL-2 ratio, driving apoptosis through PARP1 activation. Notably, the organism's intrinsic vancomycin resistance enables its survival and expansion during CDI treatment, fostering its emergence as a pathobiont. Our results demonstrate that toxigenic C. difficile facilitates C. innocuum epithelial invasion and exacerbates host cell damage through synergistic interactions. These findings highlight C. innocuum as a clinically relevant pathobiont, emphasizing the need for improved diagnostics and targeted strategies in CDI management.
Insights
Clostridium innocuum worsens outcomes in Clostridioides difficile infection (CDI) by enhancing cell damage and barrier disruption. Its vancomycin resistance allows it to thrive during treatment, highlighting its role as a pathobiont.
Area of Science:
- Microbiology
- Pathogenesis
- Host-pathogen interactions
Background:
- Clostridium innocuum is increasingly found in patients with Clostridioides difficile infection (CDI).
- Its pathogenic role and cytotoxic mechanisms, especially in conjunction with C. difficile, are not well understood.
- C. innocuum's intrinsic vancomycin resistance contributes to its persistence during CDI treatment.
Purpose of the Study:
- To investigate the synergistic interactions between C. difficile and C. innocuum in human intestinal epithelial cells.
- To elucidate the mechanisms by which C. innocuum influences host cell damage and barrier function during co-infection.
Main Methods:
- Co-infection models using toxigenic C. difficile and C. innocuum in human intestinal epithelial cells.
- Assessment of cytotoxicity, epithelial barrier integrity, and host cell apoptosis pathways (p53, BAX/BCL-2, PARP1).
Main Results:
- C. innocuum alone showed minimal cytotoxicity, but significantly increased cell death and barrier disruption when co-infecting with C. difficile.
- C. difficile pre-infection facilitated C. innocuum translocation, indicating toxin-mediated barrier damage aids colonization.
- Co-infection activated p53 signaling and modulated the BAX/BCL-2 ratio, promoting apoptosis via PARP1.
Conclusions:
- Toxigenic C. difficile facilitates C. innocuum invasion and exacerbates host cell damage through synergistic interactions.
- C. innocuum acts as a clinically relevant pathobiont in CDI, particularly under vancomycin treatment.
- Findings underscore the need for improved diagnostics and targeted therapeutic strategies for managing CDI co-infections.
More Related Videos
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
09:49Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection
Published on: November 18, 2022
Related Concept Videos
Bacterial Toxins
Bacterial Flora of the Large Intestine
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Bacterial Gastroenteritis
Introduction to the Human Microbiota
Microbiota of the Large Intestine